Minimal change disease following autologous stem cell transplant for Hodgkin lymphoma

BMJ Case Rep. 2025 Jan 23;18(1):e259306. doi: 10.1136/bcr-2023-259306.

Abstract

Nephrotic syndrome is characterised by heavy proteinuria secondary to glomerular injury. It is an uncommon but serious complication of allogeneic haematopoietic stem cell transplant (HSCT), but rarely reported after autologous HSCT. Here, we report the case of a man in his mid-20s who presented with significant peripheral oedema 2 months after autologous HSCT for Hodgkin lymphoma. Investigations demonstrated nephrotic range proteinuria and hypoalbuminaemia. Renal biopsy demonstrated minimal change disease. Initial treatment with glucocorticoids was complicated by toxicity without remission. However, the clinical and biochemical resolution of his nephrotic syndrome promptly followed administration of rituximab. This case highlights nephrotic syndrome as a complication after autologous HSCT and suggests potential effectiveness of rituximab in minimal change disease in the presence of steroid toxicity or other contraindications.

Keywords: Haematology (incl blood transfusion); Nephrotic syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hodgkin Disease* / therapy
  • Humans
  • Male
  • Nephrosis, Lipoid* / diagnosis
  • Nephrosis, Lipoid* / etiology
  • Nephrotic Syndrome / etiology
  • Rituximab* / therapeutic use
  • Transplantation, Autologous*

Substances

  • Rituximab
  • Antineoplastic Agents, Immunological